Theranostics: New hope for late stage prostate cancer patients with an innovative UK-first treatment
3 June, 2019
Theranostics is a personalised cancer treatment that combines diagnostics and therapy to detect and treat late stage prostate cancer and neuroendocrine tumours. GenesisCare Windsor is the first centre in the UK to make 177Lutetium PSMA, a personalised therapy for patients with advanced prostate cancer, clinically available. Windsor, UK, 3 June 2019 – The first patients…
16 May, 2019
SpaceOAR® Hydrogel as part of our standard pre-radiotherapy treatment.
We believe patients deserve the best and that’s why we offer SpaceOAR® Hydrogel as part of our standard pre-radiotherapy treatment. We design our care to help give patients the best possible life outcomes. Which is why since January 2018 we’ve successfully delivered 200 SpaceOAR® Hydrogel insertions as part of our standard pre radiotherapy treatment for…
9 May, 2019
New look at GenesisCare centres. We are excited to share that we’ve started the installation of a fresh new look at our UK centres. So far 6 of our centres have had the new signage installed and plans are in place to complete the other 6. The new signage makes it easier for patients to…
11 March, 2019
GenesisCare, the largest private provider of cancer and cardiac healthcare in Australia and Europe, announced today that KKR’s investment in the Company had successfully completed. The transaction was originally announced in October 2018. Since that time, the transaction has received approval from GenesisCare shareholders and regulatory clearance from relevant authorities in Australia, Europe and China….
7 February, 2019
GenesisCare and the University of Oxford establish innovative 10-year research partnership
GenesisCare and the University of Oxford establish innovative 10-year research partnership to improve diagnosis and care for people with cancer 10-year partnership established between the UK’s largest private provider of radiotherapy and world-leading university to drive cancer research and improve care services across the UK Major investment will bring advanced radiotherapy technology to the UK…
20 December, 2018
Karthik is a Consultant Haematologist at Oxford University Hospitals NHS Trust and GenesisCare’s new Clinical Director for haematology services. Karthik is also the Director of the Oxford Myeloma Translational Research Centre, the Lead Clinician for myeloma and other plasma cell dyscrasias at the Thames Valley Strategic Clinical Network, Divisional Lead for Cancer research for National…